Adlarity®, a once-weekly patch that delivers consistent doses of donepezil, is now available to treat adults with mild, moderate, or severe dementia of the Alzheimer type.
Adlarity is for transdermal administration of donepezil, an acetylcholinesterase inhibitor. Each patch delivers either 5 mg or 10 mg of donepezil daily for 7 days, after which it is removed and a new patch is applied. Patients treated with donepezil hydrochloride 5 mg or 10 mg tablets may be switched to Adlarity.
The patch was approved in March 2022 based on a relative bioavailability study in healthy patients comparing the transdermal system to Aricept tablets. Findings showed that once weekly Adlarity was comparable to daily donepezil tablets.
Adhesion was evaluated in a clinical study in 85 patients, each wearing an Adlarity 10 mg/day for 168 hours on the back for 4 consecutive weeks. Results showed 307 of the 338 patches (91%) exhibited 80% or greater surface area adhesion at all timepoints evaluated.
In a press release, Corium, the manufacturer, stated that they are working toward greater patient accessibility through government-sponsored programs, including Medicare Part D, with coverage expected to begin in 2023. The Company has also launched a patient support program for eligible commercially-insured patients.
This article originally appeared on MPR
- Corium Launches ADLARITY® (donepezil transdermal system) for Patients with Alzheimer’s Dementia. News release. Corium, Inc. Accessed September 29, 2022. https://www.prnewswire.com/news-releases/corium-launches-adlarity-donepezil-transdermal-system-for-patients-with-alzheimers-dementia-301636317.html
- Adlarity. Package insert. Corium, Inc.; 2022. Accessed September 29, 2022. https://www.corium.com/products/ADLARITY/ADLARITY_PI_ENGLISH_US.pdf